CIK Cell Transfusion Plus Gefitinib As Second Or Third-Line Treatment for Advanced Adenocarcinoma Non-Small Cell Lung Cancer

Inclusion Criteria: * Age between 18 to 80 years * Histologically or cytologically proven advanced adenocarcinoma non-small-cell lung cancer * Life expectancy more than 12 weeks * Not received EGFR agent or cell immunotherapy before entry into this study * World Health Organization- Eastern Cooperative Oncology Group Performance Status 0-3 * Gefitinib as the second or third line therapy * More than 4 weeks must have completion of the last dose of chemotherapy, radiation therapy, investigational therapy and patients must adequately recover from these effects * Disease measurable * Patients must have adequate organ and marrow functions as defined below: white blood cells: more than 3.0×109/L, Neutrophils: more than 1.5×109/L, Platelets: more than 75×109/L, Hemoglobin more than 80g/L, Serum total bilirubin less than 1.25 folds of the upper normal limit (ULN), Serum glutamic-oxal (o) acetic transaminase: less than 2.5×ULN, Serum glutamate pyruvate transaminase: less than 2.5×ULN, Serum creatinine: less than 1.25×ULN, Blood urea nitrogen: less than 2×ULN. * Pregnancy test: the test of women of child-bearing period must be negative before entry into this study * Subject must have good compliance and voluntarily to sign a written informed consent Exclusion Criteria: * Acute infection * Uncontrolled concurrent illness: hypersensitiveness, asthma, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, serious heart valve disease * Psychiatric illness, pharmacological dependence, or other situation that would limit compliance with study requirements * History of other neoplasms * Coagulation disorder and bleeding tendency * Pertinacious hypertension（systolic blood pressure \> 140 mmHg or diastolic blood pressure \> 90 mmHg) after aggressive therapy * Brain metastasis with symptomatic * Severe liver dysfunction * Autoimmune disease (e.g. systemic lupus erythematosus, rheumatoid arthritis, thyroadenitis, et al ) * Patients who diagnosed as virus hepatitis, syphilis or HIV, or other infectious diseases * Employment of corticosteroids or other immunodepressive hormone therapies * With main organs transplantation * Pregnant or lactating women * Known or suspected in patients with severe hypersensitivity to CIK or gefitinib or to any other component of gefitinib * Patients receiving any other investigational agents in 30 days or prepare to participate in other investigation in the clinical period